About this trial
A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples.
In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
respiratory failure;
hip fracture;
Injury Severity Score no higher than 8 points.
Disqualifiers
terminal condition of the patient;
shock;
paradoxical pathological breathing;
hypertensive crisis;
Trial design
Parallel
Treatments tested in this trial
Vibrolung
DeviceBARK VibroLUNG vibroacoustic device (No. RK-MT-7No.013611 dated October 7, 2014). The device is designed for the treatment and prevention of respiratory diseases. The device operates on the principle of exposure to a powerful vibroacoustic signal generated by special emitters. During the procedure, the emitters are pressed against the surface of the chest, and the procedure lasts an average of 5 minutes. The frequency of the signal constantly changes and has complex modulation, which ensures maximum effectiveness. Depending on the selected program, the signal can cause the effect of percussion, soft vibration, smooth alternation of acoustic signal and vibration, or combinations thereof.
Treatment groups
Trial outcomes
Primary outcomes
Arterial blood gases
On day 1 of vibroacoustic therapy, arterial blood sampling will be performed to determine PaO2 (mmHg), PaC02 (mmHg), as well as for dynamics during transfer to the specialized department.
Secondary outcomes
Chest X-ray
Chest X-ray at admission and after vibroacoustic therapy sessions at least twice in total, with technical capabilities(The X-ray image)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.